Skip to main content

Volume 16 Supplement 2

The 21st International Conference on Bioinformatics (InCoB2022): medical genomics

Research

Publication of this supplement has not been supported by sponsorship. Information about the source of funding for publication charges can be found in the individual articles. The articles have undergone the journal's standard peer review process for supplements. The Supplement Editors declare that they have no competing interests.

Virtual21-23 November 2022

Conference website

Edited by Shoba Ranganathan, Prashanth Suravajhala, Yun Zheng, and Kenta Nakai.

  1. Alzheimer’s disease (AD) is an incurable, debilitating neurodegenerative disorder. Current biomarkers for AD diagnosis require expensive neuroimaging or invasive cerebrospinal fluid sampling, thus precluding e...

    Authors: Sherlyn Jemimah and Aamna AlShehhi
    Citation: BMC Medical Genomics 2023 16(Suppl 2):244
    Content type: Research Published on:
Submit manuscript

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.1
    5-year Journal Impact Factor: 2.5
    Source Normalized Impact per Paper (SNIP): 0.581
    SCImago Journal Rank (SJR): 0.703

    Speed 2023
    Submission to first editorial decision (median days): 34
    Submission to acceptance (median days): 164

    Usage 2023
    Downloads: 1,335,753
    Altmetric mentions: 593

Peer-review Terminology

  • The following summary describes the peer review process for this journal:

    Identity transparency: Single anonymized

    Reviewer interacts with: Editor

    Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

    More information is available here

Follow

Sign up for article alerts and news from this journal

BMC Medical Genomics

ISSN: 1755-8794

Contact us